A Marine-Derived Anticancer Compound Targeting Novel Binding Sites of Carbonic Anhydrase IX in Lung Cancer
Introduction
Hypoxia is a defining hallmark of solid tumors and a major contributor to cancer progression, metastasis, and resistance to therapy. Among hypoxia-regulated enzymes, Carbonic Anhydrase IX (CAIX) plays a pivotal role in maintaining tumor pH homeostasis by promoting extracellular alkalosis and intracellular acidosis—conditions that favor cancer cell survival. Because of its selective overexpression in hypoxic tumors, CAIX has emerged as a promising therapeutic target, particularly in lung adenocarcinoma.
In a recent study published in Pharmaceuticals (MDPI), researchers report the discovery of a novel marine-derived cinnamyloxyl derivative isolated from the seagrass Cymodocea serrulata. This compound demonstrates potent anticancer activity against A549 lung adenocarcinoma cells by binding to previously unexplored sites of CAIX, distinguishing it from conventional sulfonamide-based inhibitors.
Discovery of a Novel Marine Cinnamyloxyl Derivative
The identified compound,
3-(E-3,4-dihydroxycinnamoyloxyl)-2-hydroxypropyl-9Z,12Z-octadeca-9,12-dienoate,
represents a unique class of naturally occurring CAIX inhibitors.
Marine plants such as seagrasses are increasingly recognized as reservoirs of structurally diverse bioactive molecules. This study highlights C. serrulata as a valuable source of anticancer compounds with novel molecular mechanisms.
Experimental Approach
The anticancer potential and molecular mechanism of the compound were evaluated using a comprehensive experimental framework:
-
Cell viability assays (MTT) to determine cytotoxicity
-
Fluorescent staining (AO/PI/DAPI) for apoptosis and nuclear damage
-
Flow cytometry (FACS) for mitochondrial membrane potential (MMP) and cell-cycle analysis
-
qPCR and Western blotting to assess gene and protein expression of CAIX and apoptotic markers (BAX, BAD)
-
Molecular docking and molecular dynamics (MD) simulations to evaluate binding affinity and complex stability
Doxorubicin was used as a reference chemotherapeutic agent for comparison.
Key Findings
1. Potent Cytotoxicity Against A549 Cells
The compound exhibited strong anticancer activity with an IC₅₀ of 11.61 µM, outperforming doxorubicin (IC₅₀: 13.7 µM). This indicates a high level of efficacy at comparatively lower concentrations.
2. Disruption of Tumor pH Regulation
Under hypoxic conditions, untreated cells showed minimal extracellular pH change (ΔpHe = 0.15), whereas compound-treated cells displayed a marked increase (ΔpHe = 0.6). This suggests effective inhibition of CAIX-mediated pH regulation, leading to intracellular acidosis and reduced tumor cell survival.
3. Induction of Mitochondrial-Mediated Apoptosis
Treatment caused:
-
Loss of mitochondrial membrane potential
-
DNA fragmentation
-
S-phase cell-cycle arrest
At the molecular level, qPCR analysis revealed:
-
Downregulation of CAIX (~0.9-fold)
-
Upregulation of pro-apoptotic genes
-
BAX: 5.2-fold increase
-
BAD: 3.08-fold increase
-
These findings confirm activation of intrinsic apoptotic pathways.
Unique CAIX Binding Mechanism
In silico docking studies revealed a binding affinity of −7.55 kcal/mol, supported by molecular dynamics simulations showing stable CAIX–compound interactions for over 100 ns.
Crucially, the compound binds to glutamine (Gln242) and alanine (Ala392) residues near the central Zn²⁺ atom of CAIX. This binding mode is fundamentally different from classical sulfonamide inhibitors, which typically interact with the zinc ion via sulfonamide groups.
This novel interaction profile may:
-
Reduce resistance mechanisms
-
Improve selectivity toward hypoxic tumor cells
-
Open new avenues for CAIX inhibitor design
Therapeutic Implications
By disrupting CAIX function under hypoxic conditions, the compound weakens the cancer cell’s defense against reactive oxygen species (ROS), thereby enhancing susceptibility to apoptosis. Its marine origin, unique binding sites, and superior cytotoxic profile position it as a promising lead molecule for future anticancer drug development.
Conclusion
This study provides compelling evidence that a naturally derived cinnamyloxyl compound from Cymodocea serrulata acts as a potent and mechanistically distinct CAIX inhibitor. Its ability to target novel binding sites, induce mitochondrial apoptosis, and outperform a standard chemotherapeutic agent underscores its potential in treating hypoxic lung adenocarcinomas.
Key words:
Hashtags:
Visit our page : computationalbiologists.com
Nominations page : https://computationalbiologists.com/award-nomination/?ecategory=Awards&rcategory=Award
Instagram : https://www.instagram.com/_awardresearcher_02/
Blogger : https://www.blogger.com/blog/posts/859633461166750462
Twitter : https://x.com/AwardResearcher
Facebook : https://www.facebook.com/profile.php?id=61573772493321
Tumblr : https://www.tumblr.com/computationalbiologistsawards?source=share
Pintrest : https://in.pinterest.com/awardresearcher/_profile/
Youtube : https://www.youtube.com/@ResearcherAward
Comments
Post a Comment